When Cardium Therapeutics recently acquired To Go Brands, a San Diego based nutraceuticals developer, it was a major expansion of Cardium’s original Medpodium nutraceutical line, and reflective of the company’s support for the nutraceutical side of their business. Cardium, known for its developments in the area of regenerative medicine, is also becoming a growing player in the area of wellness and disease prevention. To Go Brand products cover a range of weight-loss and energy markets for active professionals, but also include the following offerings designed to promote basic nutritional health:
• Healthy Belly is a probiotic digestive mix of live “friendly” bacteria that are beneficial when consumed daily for maintaining digestive balance. For hundreds of years dairy foods containing live cultures have been touted as having beneficial digestive and intestinal properties. Now increasing numbers of health-conscious people are seeking more convenient ways to add the benefits of probiotics to their diets. Each packet contains natural probiotic cultures plus fiber that can help regulate the digestive system.
• Go Greens Super Fruits & Veggies is packed with more than 15 organic fruits and veggies to provide an antioxidant powder equivalent to 6 servings of fruits and vegetables, and with a great taste. One serving of Go Greens has an Oxygen Radical Absorbance Capacity (ORAC) value of 4000. As a comparison, a serving of broccoli has an ORAC value of 700.
• Omega To Go provides 100 mg of Vegetarian Omega in an orange dreamsicle flavor, is packed with antioxidants from Vitamins A, C, E, and D, and is a good source of fiber for healthy digestion. It also contains life’sDH™, one of the only vegetarian sources of DHA on the market today. Unlike oils derived from fish that may be high in ocean-borne contaminants, life’sDH™ comes from eco-friendly, sustainable algae. Fish actually get their high DHA content by eating algae, and life’sDH™ simply eliminates the “middle fish.”
For additional information, visit www.CardiumTHX.com and www.ToGoBrands.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Monday, December 31, 2012
Bergamo Acquisition Corp. (BGMO) Offers an Alternative to Developing Nations
It’s a sad fact that hundreds of millions of people around the world do not have regular access to the fundamental requirements of a healthy life, such as clean water or basic electrical power. Every year millions of people, many of them children, perish as the result of water related diseases, almost all of them in developing nations. To make matters worse, millions of people are added to cities in these countries every year, cities that do not even have the utilities to support their existing inhabitants. World population is projected to top 8 billion over the next 20 years, with almost all of that growth occurring in developing countries.
Electrical power is a key factor in securing and distributing a dependable supply of clean drinking water. In the past, there were few options for generating such power without the construction of traditional centralized power plants, but conventional power generation is costly, requiring significant investments in plants, transmission networks, and logistics infrastructure. In addition, fossil fueled plants pose environmental threats that few developing countries are willing to accept. Today, however, new technologies make alternative energy a viable choice.
Bergamo’s long term goal is to be the leading supplier of renewable electricity and clean drinking water to millions of people inhabiting urban and rural areas across the globe. Through Bergamo Acquisition’s subsidiary in Florida, Bergamo Energy, the company’s engineers have developed solar generators for home and industry applications, as well as solar operated tube well water pumping systems, to meet the vast energy needs of emerging markets. For example, the economically advanced 5 MW Hybrid Solar Thermal Power Plant is designed to produce more than 40 GWh of base load power with an oversized solar field yielding a 25% capacity factor, and, when operational, is designed to provide power for up to 20,000 average homes. Such plants have advantages over photovoltaics in terms of their fuel flexibility and longevity. Each 5 MW CSP plant can also provide up to 250,000 gallons daily of potable water from a brackish or seawater source in conjunction with electricity generation, and only 30 acres of land is required to install 5 MW power plants.
For additional information, visit the Bergamo website at www.BergamoCorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Electrical power is a key factor in securing and distributing a dependable supply of clean drinking water. In the past, there were few options for generating such power without the construction of traditional centralized power plants, but conventional power generation is costly, requiring significant investments in plants, transmission networks, and logistics infrastructure. In addition, fossil fueled plants pose environmental threats that few developing countries are willing to accept. Today, however, new technologies make alternative energy a viable choice.
Bergamo’s long term goal is to be the leading supplier of renewable electricity and clean drinking water to millions of people inhabiting urban and rural areas across the globe. Through Bergamo Acquisition’s subsidiary in Florida, Bergamo Energy, the company’s engineers have developed solar generators for home and industry applications, as well as solar operated tube well water pumping systems, to meet the vast energy needs of emerging markets. For example, the economically advanced 5 MW Hybrid Solar Thermal Power Plant is designed to produce more than 40 GWh of base load power with an oversized solar field yielding a 25% capacity factor, and, when operational, is designed to provide power for up to 20,000 average homes. Such plants have advantages over photovoltaics in terms of their fuel flexibility and longevity. Each 5 MW CSP plant can also provide up to 250,000 gallons daily of potable water from a brackish or seawater source in conjunction with electricity generation, and only 30 acres of land is required to install 5 MW power plants.
For additional information, visit the Bergamo website at www.BergamoCorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Guitammer Company, Inc. (GTMM) Management Links Arms with Shareholders
One of the things investors look for in a company is the quality of the management team and the alignment of the team’s personal interests with those of the company’s shareholders. Do key executives have a direct personal interest in the company, or is their involvement strictly professional? The Guitammer Company answered that question with their recent Form 4 filings with the SEC.
CEO Mark Luden received no increase in pay this past year (or in prior years), but was instead compensated with options for 3 million shares at an exercise price of $0.25 per share. It was compensation based largely upon a number of important accomplishments, including obtaining a patent for the company’s pioneering BK Live! technology, and taking the company public via a Form 10, as well as successfully raising money and converting debt. It shows clearly the intent of management and the Board to keep cash in the company, to speed development, and to incentivize management to achieve company goals.
Such an approach demonstrates management’s belief in the company’s revolutionary technology. The Guitammer Company, based in Ohio, is in the process of changing the way people watch sports and other broadcast entertainment, and believes it has the best platform and broadcast technology to allow users to actually feel live action sports and other events, revolutionizing the viewing experience much like Dolby has done with their patents on surround sound or TiVo has done with television viewing.
The Guitammer Company is a leader in low frequency sound products and technology, with award-winning innovations, through their ButtKicker brand, that let users feel low-frequency sound in ways never before possible. The frequencies they work with are below the audible level, so the user doesn’t hear the sound, but actually feels it. As a result, users are immersed in the sound-feeling experience, whether at home or elsewhere, without having to worry about excessive volume that could annoy others or even damage hearing. Their products are now used around the world by such entertainment and theater companies as AMC, IMAX, and Disney, and by world famous musicians, as well as with in-home theaters and advanced car audio systems.
For more information, visit www.Guitammer.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
CEO Mark Luden received no increase in pay this past year (or in prior years), but was instead compensated with options for 3 million shares at an exercise price of $0.25 per share. It was compensation based largely upon a number of important accomplishments, including obtaining a patent for the company’s pioneering BK Live! technology, and taking the company public via a Form 10, as well as successfully raising money and converting debt. It shows clearly the intent of management and the Board to keep cash in the company, to speed development, and to incentivize management to achieve company goals.
Such an approach demonstrates management’s belief in the company’s revolutionary technology. The Guitammer Company, based in Ohio, is in the process of changing the way people watch sports and other broadcast entertainment, and believes it has the best platform and broadcast technology to allow users to actually feel live action sports and other events, revolutionizing the viewing experience much like Dolby has done with their patents on surround sound or TiVo has done with television viewing.
The Guitammer Company is a leader in low frequency sound products and technology, with award-winning innovations, through their ButtKicker brand, that let users feel low-frequency sound in ways never before possible. The frequencies they work with are below the audible level, so the user doesn’t hear the sound, but actually feels it. As a result, users are immersed in the sound-feeling experience, whether at home or elsewhere, without having to worry about excessive volume that could annoy others or even damage hearing. Their products are now used around the world by such entertainment and theater companies as AMC, IMAX, and Disney, and by world famous musicians, as well as with in-home theaters and advanced car audio systems.
For more information, visit www.Guitammer.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
International Stem Cell Corp. (ISCO) Breakthrough in Human Clinical-Grade Stem Cells Safely Halts Rejection
International Stem Cell Corp. reported some ground-breaking news recently, showcasing the progress the company has made towards clinical-grade, applied stem cell therapy, with the announcement that the R&D team has successfully created the first human, clinical-grade stem cell lines able to immune-match millions of people and thus sharply reduce rejection by the individual’s immune system.
This revolutionary breakthrough is an extension of ISCO’s established research-grade parthenogenetic stem cell (hpSC) technology, proprietarily engineered and designed from the ground up to align perfectly with FDA regulations, as well as the Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) standards they helped create to ensure quality control for the clinical space. These new lines have been validated as HLA coding region-homozygous (simple gene profile in the areas which code for immune rejection) by independent third party testing, a feature which not only gives them a distinct clinical advantage due to patient-specific immune matching capability (huge reduction in rejection by the host immune system), but also further clearly sets the technology apart from embryonic stem cells.
An immune type contained within the company’s existing hpSC lines affords potential to immune-match some 70M people and is the most common type in the entire Caucasian populace. Development of clinical grade lines from this rock-solid foundation is now enabling ISCO to transcend previous limitations and initiate U.S. clinical trials. Think about the impact of ISCO being able to supply the global medical community with a nearly limitless supply of viable, FDA-compliant stem cells which have this immune-matching capability, the upside to patients alone is enough to make headlines.
CEO of ISCO and Co-Chairman of the Board, Andrey Semechkin, PhD, was boldly confident about the success rate of the new stem cell lines to immune-match millions (the core technology is proven after all) and underscored how the GMP compliance opens access to a massive network of clinical pipelines. Safe, feature-rich cell and tissue development from this incredible technology platform should tear down several walls in the clinical arena, as the promise of commercial therapies from pluripotent human stem cells (from unfertilized eggs) now appears well within striking distance.
Being able to generate such highly-functional therapeutic cells, as well as downstream cell-based therapeutic research and cosmetic products (for the company’s Lifeline Cell Technology and Lifeline Skin Care subsidiaries), puts ISCO in an extremely favorable position as this milestone breaks. Something detailed by Exec. VP of ISCO, Simon Craw, PhD., who went on to elaborate how the significance of this platform technology’s development cannot be underestimated, both for the life science/medical community and for shareholders as well. Dr. Craw called it a critical milestone for ISCO on the road to becoming a clinical stage company and reaffirmed how the development shores up ISCO’s broader leadership position in the stem cell technology field.
This new immune-matching marvel will add to the company’s already impressive Stem Cell Bank, which is emerging as the first ever collection framework of non-embryonic, histocompatible human stem cells for the life science industry’s most advanced work. We have here, in this technology, a framework to test therapies and from which to engineer them, that stands to change the face of medicine itself. This is one of the final hurdles to clear before the biotech company ISCO goes supernova and it will be quite interesting to see how clinical development advances in the coming months.
The potential impact for severe degenerative diseases of the eye, nervous system, and liver, where this technology has already proven itself clinically, but was not viable due to an inability to provide comprehensive immune-matching, is immense and the entire area now opens up like a vast new frontier. ISCO is already geared up to pioneer that land and has set out to stake claim to a lucrative, untrammeled territory, whose mastery should translate directly into substantial shareholder growth over the long-term.
This revolutionary breakthrough is an extension of ISCO’s established research-grade parthenogenetic stem cell (hpSC) technology, proprietarily engineered and designed from the ground up to align perfectly with FDA regulations, as well as the Good Tissue Practice (GTP) and Good Manufacturing Practice (GMP) standards they helped create to ensure quality control for the clinical space. These new lines have been validated as HLA coding region-homozygous (simple gene profile in the areas which code for immune rejection) by independent third party testing, a feature which not only gives them a distinct clinical advantage due to patient-specific immune matching capability (huge reduction in rejection by the host immune system), but also further clearly sets the technology apart from embryonic stem cells.
An immune type contained within the company’s existing hpSC lines affords potential to immune-match some 70M people and is the most common type in the entire Caucasian populace. Development of clinical grade lines from this rock-solid foundation is now enabling ISCO to transcend previous limitations and initiate U.S. clinical trials. Think about the impact of ISCO being able to supply the global medical community with a nearly limitless supply of viable, FDA-compliant stem cells which have this immune-matching capability, the upside to patients alone is enough to make headlines.
CEO of ISCO and Co-Chairman of the Board, Andrey Semechkin, PhD, was boldly confident about the success rate of the new stem cell lines to immune-match millions (the core technology is proven after all) and underscored how the GMP compliance opens access to a massive network of clinical pipelines. Safe, feature-rich cell and tissue development from this incredible technology platform should tear down several walls in the clinical arena, as the promise of commercial therapies from pluripotent human stem cells (from unfertilized eggs) now appears well within striking distance.
Being able to generate such highly-functional therapeutic cells, as well as downstream cell-based therapeutic research and cosmetic products (for the company’s Lifeline Cell Technology and Lifeline Skin Care subsidiaries), puts ISCO in an extremely favorable position as this milestone breaks. Something detailed by Exec. VP of ISCO, Simon Craw, PhD., who went on to elaborate how the significance of this platform technology’s development cannot be underestimated, both for the life science/medical community and for shareholders as well. Dr. Craw called it a critical milestone for ISCO on the road to becoming a clinical stage company and reaffirmed how the development shores up ISCO’s broader leadership position in the stem cell technology field.
This new immune-matching marvel will add to the company’s already impressive Stem Cell Bank, which is emerging as the first ever collection framework of non-embryonic, histocompatible human stem cells for the life science industry’s most advanced work. We have here, in this technology, a framework to test therapies and from which to engineer them, that stands to change the face of medicine itself. This is one of the final hurdles to clear before the biotech company ISCO goes supernova and it will be quite interesting to see how clinical development advances in the coming months.
The potential impact for severe degenerative diseases of the eye, nervous system, and liver, where this technology has already proven itself clinically, but was not viable due to an inability to provide comprehensive immune-matching, is immense and the entire area now opens up like a vast new frontier. ISCO is already geared up to pioneer that land and has set out to stake claim to a lucrative, untrammeled territory, whose mastery should translate directly into substantial shareholder growth over the long-term.
For more information on International Stem Cell Corp., visit
www.InternationalStemCell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with
companies that have huge potential to succeed in the short and long-term
future. We offer several ways for investors to learn more about investing in
these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Friday, December 28, 2012
New Western Energy Corp. (NWTR) is “One to Watch”
New Western Energy continues piecing together an extremely solid portfolio of working interests across the rich hydrocarbon targets of the Gulf States region, with noted small-cap research firm, Zacks Equity Research, even bumping the price target ten cents recently (Dec 21) to $1.40 on the company’s strong market cap to reserves ratio among others things, especially in light of the new Fields Lease acquisition in Kansas (Dec 20).
The 300-acre Fields Lease (100% WI) has expanded an already firm, contiguous foundation in the Chautauqua Arch area held by the company via their 1.7k-acre B&W Ranch (90% WI, acquired in March of 2012) and 550-acre Smith Leases (90% WI, acquired in May of 2012). This brings NWTR up to 2,550 acres in prime Pennsylvanian age Cherokee basin shale, all of it contiguous (with southern district targets in the pre-Pennsylvanian reservoirs like the Weiser Sands and Wayside Sands). The gas and oil here flows from primarily the Mulky Shale and Weiser Sands reservoirs, offering up a target rich environment for new wells, and the company is laser-focused on acquiring additional interests in the Chautauqua County area (and elsewhere) through carefully selected acquisitions/partnerships.
Looking at the new reserve estimate, post the Fields Lease acquisition, Zacks was confident of the upwardly revised price target from eleven days prior, showing some really nice forward revenue projections as well (ramping from $0.20M in Q1 2013 to $1.7M in Q4 the following year). The B&W Ranch Lease (engineering, reserve, and geological analysis via the Apr 25 agreement with Carroll Energy, LLC) for instance has such a great target array there is already obvious potential for three to four oil formation discoveries by NWTR, in addition to an equal number of gas formation discoveries. Both production zones are in quite shallow territory and in general we have reservoirs at a very manageable depth of around 600 to 1.4k feet across the leases, offering shareholders an approachable, economically feasible growth outlook.
Turning further south past where the Central Oklahoma platform meets the Cherokee basin, across the border and east of Tulsa in Rogers County, are the company’s Oklahoma assets. These assets include the over 120-acre Glass Lease (60.94% NRI) consisting of 14 wells secured via joint-venture with RC Oil Company back in 2009 and the 150-acre Glass Lease (60.94% NRI), also via the RC Oil JV. The properties are now overseen/operated by Petroleum Energy Management Co. (PEMCO), who secured the interests towards the end of 2011.
PEMCO wrapped Phase I of the newest work-over program on the Glass Lease in September of 2012, with emphasis being primarily on jacking up output from the 6 production wells through redirected pressure maintenance and plugging of extraneous wells. Production continues on the site and the indicated probable/recoverable reserves were last calculated at around 287k bbls of oil from the Bartlesville Formation. The Phillips Lease has seven wells and one saltwater injection well, with shallow targets in the 500-foot range and 20 year old wells that are still producing like champs. The outlook is quite positive, especially considering the abundance of production in the district itself and ample room to work with at 150 acres.
Jumping further to the south we have a set of five leases in Texas, located in Jones and Shackelford Counties, which make up the bulk of the company’s remaining oil and gas production interests. It’s a good idea to look at the Moran Lease (12 wells, eight lease units total) in Shackelford County first, as this 680-acre property recently (Oct 16) saw commencement of a comprehensive work-over program via the company’s wholly-owned, Royal Texan Energy Co. subsidiary, focused on the Sam Cannon Well Unit. The two wells (#1 and #4) which make up the Sam Cannon churned out some 146.6k bbls of oil and 4.851M MCF of gas from August 1966 to February 1997, seeing 196 BOPD figures ($1.5M per quarter at current prices). Production is in the Mississippian zone (with a deeper Ellenberger secondary) at 3.9k feet but a packer and tubing section is lodged at around 2.5k feet in the #1 and was being pulled at last report from the well bore in advance of production restart.
The most recent Geologist Report on the Moran Lease (which was picked up via the Royal Texan acquisition in January of 2012), pegged the combined recoverable reserves at over 183.8k bbls and 3.791M MCF of gas. Anticipation is high at NWTR to bring Moran output back up to past production levels while improving recovery efficiency by as much as 30%, with output steadily ramping up as the work-over program advances through 2013. Also acquired along with Royal Texan was the 580-acre Trice Lease, which has a series of 24 wells on the property in the shallow (500 to 700 feet) King Sand formation, as well as a battery of six injection wells. Trice saw the start of a work-over program as well in 2012 (April 9), with primary goals being a cost-effective increase in production rates, and work focused on four of the key wells (numbers 1, 3, 16, and 18).
The other three Texas interests are in Jones County. The primary, 160-acre Swenson Lease is part of a JV with Texas-based operator, 3-M Production, via the company’s wholly-owned subsidiary, New Western Texas Oil and Gas Corp. The Swenson saw good test drilling in March of 2011 that validated the sand and rock formation on-site. Subsequent geological analysis offers positive indications that as many as two more wells will be required in total to drain the entire field and all of the key elements have been identified as present at Swenson for considerable future production to take place, from hydrocarbon abundance in the reservoir rock, to the existence of a pronounced trapping mechanism. The property is sitting in the heart of some serious production history as well, including the Griffin Field (0.75 miles west) and the Iron Mountain – Avoca Pool Field (0.5 miles northeast), which collectively have produced in excess of a whopping 19.6M bbls.
The Reves (84 acres with targets in the Flippen Sand, Gunsight Lime, and Swastika Sand in the 1k to 3k foot range) and McLellan Leases (160 acres with similar targets to Swenson and Reves) are adjacent to the Swenson and roundly reinforce an already strong acreage footprint. The McLellan is just a thousand feet northwest of the Jones County Regular Field, which has output some 40.6k bbls from the Flippen/Swastika Sands, and the company sees a lot of production potential here.
Finally, over in Pennsylvania’s Tioga County, we have the 23-acre Wellsboro Lease (100% WI) with a clear lead from a 1985 study that inferred the presence of a large (900k cubic yards) formation believed to be part of the state’s famous Marcellus Shale that could turn into a sizeable natural gas discovery for the company. The site is a glacial-aged kame terrace where hydrocarbons apparently got trapped by glacial ice.
The Zacks report shows some $24k in revenue at the end of Q3 2012, up 57.8% from Q2, a figure projected to grow from around $135k in Q1 of 2013, up to over $478k in Q4 2013 as multiple production wells come online, with the business growing from just a handful of stable producers to as many as 25 highly-efficient ones. Veteran leadership stands behind the aggressive portfolio management strategy at NWTR and it is quite clear to even the lay investor that the company has developed a compelling array of proven reserves backed up by the financial flexibility and pro-partnership attitude needed to delimit growth risk for the shareholders.
For more information on New Western Energy, visit www.NewWesternEnergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The 300-acre Fields Lease (100% WI) has expanded an already firm, contiguous foundation in the Chautauqua Arch area held by the company via their 1.7k-acre B&W Ranch (90% WI, acquired in March of 2012) and 550-acre Smith Leases (90% WI, acquired in May of 2012). This brings NWTR up to 2,550 acres in prime Pennsylvanian age Cherokee basin shale, all of it contiguous (with southern district targets in the pre-Pennsylvanian reservoirs like the Weiser Sands and Wayside Sands). The gas and oil here flows from primarily the Mulky Shale and Weiser Sands reservoirs, offering up a target rich environment for new wells, and the company is laser-focused on acquiring additional interests in the Chautauqua County area (and elsewhere) through carefully selected acquisitions/partnerships.
Looking at the new reserve estimate, post the Fields Lease acquisition, Zacks was confident of the upwardly revised price target from eleven days prior, showing some really nice forward revenue projections as well (ramping from $0.20M in Q1 2013 to $1.7M in Q4 the following year). The B&W Ranch Lease (engineering, reserve, and geological analysis via the Apr 25 agreement with Carroll Energy, LLC) for instance has such a great target array there is already obvious potential for three to four oil formation discoveries by NWTR, in addition to an equal number of gas formation discoveries. Both production zones are in quite shallow territory and in general we have reservoirs at a very manageable depth of around 600 to 1.4k feet across the leases, offering shareholders an approachable, economically feasible growth outlook.
Turning further south past where the Central Oklahoma platform meets the Cherokee basin, across the border and east of Tulsa in Rogers County, are the company’s Oklahoma assets. These assets include the over 120-acre Glass Lease (60.94% NRI) consisting of 14 wells secured via joint-venture with RC Oil Company back in 2009 and the 150-acre Glass Lease (60.94% NRI), also via the RC Oil JV. The properties are now overseen/operated by Petroleum Energy Management Co. (PEMCO), who secured the interests towards the end of 2011.
PEMCO wrapped Phase I of the newest work-over program on the Glass Lease in September of 2012, with emphasis being primarily on jacking up output from the 6 production wells through redirected pressure maintenance and plugging of extraneous wells. Production continues on the site and the indicated probable/recoverable reserves were last calculated at around 287k bbls of oil from the Bartlesville Formation. The Phillips Lease has seven wells and one saltwater injection well, with shallow targets in the 500-foot range and 20 year old wells that are still producing like champs. The outlook is quite positive, especially considering the abundance of production in the district itself and ample room to work with at 150 acres.
Jumping further to the south we have a set of five leases in Texas, located in Jones and Shackelford Counties, which make up the bulk of the company’s remaining oil and gas production interests. It’s a good idea to look at the Moran Lease (12 wells, eight lease units total) in Shackelford County first, as this 680-acre property recently (Oct 16) saw commencement of a comprehensive work-over program via the company’s wholly-owned, Royal Texan Energy Co. subsidiary, focused on the Sam Cannon Well Unit. The two wells (#1 and #4) which make up the Sam Cannon churned out some 146.6k bbls of oil and 4.851M MCF of gas from August 1966 to February 1997, seeing 196 BOPD figures ($1.5M per quarter at current prices). Production is in the Mississippian zone (with a deeper Ellenberger secondary) at 3.9k feet but a packer and tubing section is lodged at around 2.5k feet in the #1 and was being pulled at last report from the well bore in advance of production restart.
The most recent Geologist Report on the Moran Lease (which was picked up via the Royal Texan acquisition in January of 2012), pegged the combined recoverable reserves at over 183.8k bbls and 3.791M MCF of gas. Anticipation is high at NWTR to bring Moran output back up to past production levels while improving recovery efficiency by as much as 30%, with output steadily ramping up as the work-over program advances through 2013. Also acquired along with Royal Texan was the 580-acre Trice Lease, which has a series of 24 wells on the property in the shallow (500 to 700 feet) King Sand formation, as well as a battery of six injection wells. Trice saw the start of a work-over program as well in 2012 (April 9), with primary goals being a cost-effective increase in production rates, and work focused on four of the key wells (numbers 1, 3, 16, and 18).
The other three Texas interests are in Jones County. The primary, 160-acre Swenson Lease is part of a JV with Texas-based operator, 3-M Production, via the company’s wholly-owned subsidiary, New Western Texas Oil and Gas Corp. The Swenson saw good test drilling in March of 2011 that validated the sand and rock formation on-site. Subsequent geological analysis offers positive indications that as many as two more wells will be required in total to drain the entire field and all of the key elements have been identified as present at Swenson for considerable future production to take place, from hydrocarbon abundance in the reservoir rock, to the existence of a pronounced trapping mechanism. The property is sitting in the heart of some serious production history as well, including the Griffin Field (0.75 miles west) and the Iron Mountain – Avoca Pool Field (0.5 miles northeast), which collectively have produced in excess of a whopping 19.6M bbls.
The Reves (84 acres with targets in the Flippen Sand, Gunsight Lime, and Swastika Sand in the 1k to 3k foot range) and McLellan Leases (160 acres with similar targets to Swenson and Reves) are adjacent to the Swenson and roundly reinforce an already strong acreage footprint. The McLellan is just a thousand feet northwest of the Jones County Regular Field, which has output some 40.6k bbls from the Flippen/Swastika Sands, and the company sees a lot of production potential here.
Finally, over in Pennsylvania’s Tioga County, we have the 23-acre Wellsboro Lease (100% WI) with a clear lead from a 1985 study that inferred the presence of a large (900k cubic yards) formation believed to be part of the state’s famous Marcellus Shale that could turn into a sizeable natural gas discovery for the company. The site is a glacial-aged kame terrace where hydrocarbons apparently got trapped by glacial ice.
The Zacks report shows some $24k in revenue at the end of Q3 2012, up 57.8% from Q2, a figure projected to grow from around $135k in Q1 of 2013, up to over $478k in Q4 2013 as multiple production wells come online, with the business growing from just a handful of stable producers to as many as 25 highly-efficient ones. Veteran leadership stands behind the aggressive portfolio management strategy at NWTR and it is quite clear to even the lay investor that the company has developed a compelling array of proven reserves backed up by the financial flexibility and pro-partnership attitude needed to delimit growth risk for the shareholders.
For more information on New Western Energy, visit www.NewWesternEnergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Viscount Systems, Inc. (VSYS) Receives Research Coverage from SoundView Technology Group
Earlier this morning, Viscount Systems, a developer and manufacturer of IT-based solutions for physical security systems, announced that SoundView Technology Group has published a detailed report on the company. Those who wish to receive a copy of the report should email Scott Greiper at sgreiper@securesg.com.
SoundView Technology Group is known for their independent research on emerging technology companies. The research firm combines major thematic forces where technology is involved and analysis to identify the most promising companies and investment opportunities. SoundView distributes its research to institutions, investors, company managers, and individuals via proprietary platforms, the internet, and social networks.
Viscount Systems designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company’s products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
For more information on Viscount Systems and its cutting-edge technologies, visit www.Viscount.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
SoundView Technology Group is known for their independent research on emerging technology companies. The research firm combines major thematic forces where technology is involved and analysis to identify the most promising companies and investment opportunities. SoundView distributes its research to institutions, investors, company managers, and individuals via proprietary platforms, the internet, and social networks.
Viscount Systems designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company’s products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
For more information on Viscount Systems and its cutting-edge technologies, visit www.Viscount.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
PositiveID Corp. (PSID) Signs Licensing Deal with The Boeing Company
PositiveID, a developer of airborne bio-threat detection systems for the U.S. homeland defense industry and creator of advanced technologies for rapid medical testing and diabetes management, last week entered into a license and teaming agreement with The Boeing Company.
Per the agreement, which includes a license fee to PositiveID of $2.5 million, Boeing has the exclusive license to manufacture and sell PositiveID’s M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector for the U.S. Department of Homeland Security’s (DHS) BioWatch Generation 3 opportunity, as well as other opportunities that may arise in the North American market.
PositiveID will retain exclusive rights to serve as the reagent and assay supplier of the M-BAND systems to Boeing in the U.S. market, as well as keep the right to sell M-BAND units, reagents, and assays in international markets.
PositiveID’s M-BAND is a bioaerosol monitor with full capability to collect, process, detect, and analyze air samples for the detection of bacteria, viruses, and toxins. Results from individual M-BAND instruments are reported through a secure wireless network in real time to give an accurate and up to date status. The M-BAND touts significant hardiness, operating from -25 to 125 degrees Fahrenheit, for both indoor and outdoor settings. Toxin analysis takes approximately 40 minutes.
For more information, visit www.PositiveIDCorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Per the agreement, which includes a license fee to PositiveID of $2.5 million, Boeing has the exclusive license to manufacture and sell PositiveID’s M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector for the U.S. Department of Homeland Security’s (DHS) BioWatch Generation 3 opportunity, as well as other opportunities that may arise in the North American market.
PositiveID will retain exclusive rights to serve as the reagent and assay supplier of the M-BAND systems to Boeing in the U.S. market, as well as keep the right to sell M-BAND units, reagents, and assays in international markets.
PositiveID’s M-BAND is a bioaerosol monitor with full capability to collect, process, detect, and analyze air samples for the detection of bacteria, viruses, and toxins. Results from individual M-BAND instruments are reported through a secure wireless network in real time to give an accurate and up to date status. The M-BAND touts significant hardiness, operating from -25 to 125 degrees Fahrenheit, for both indoor and outdoor settings. Toxin analysis takes approximately 40 minutes.
For more information, visit www.PositiveIDCorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Thursday, December 27, 2012
Umbrella Research Initiates Coverage on TNI BioTech, Inc. (TNIB) and Sets $26 Price Target
Earlier today, TNI BioTech, a biotech company focused on utilizing patented immunotherapy to activate and mobilize the body’s immune system to combat fatal diseases, announced that Umbrella Research is now covering the company with a “buy” rating and $26 price target.
The entire 33-page report has been posted on the company’s Web site at http://www.tnibiotech.com/investor-relations/reports
The following is an excerpt of the report: “It is our opinion that TNI presents investors with significant upside from current prices based on a two-fold growth strategy including: the near term commercialization of its existing immunotherapies targeting cancer and HIV/AIDS; coupled with the potential contribution from the phase 3 study of low dose naltrexone (LDN) for use in Crohn’s disease, scheduled to begin in 2014. As the company enters 2013 it should be in a position where ramping revenue run rates not only allow it to be self-funding in regard to clinical development costs, but also for this to translate quickly into an earnings driven growth story for investors with significant potential upside from approvals.”
For more information on the company and its immunotherapies, visit www.tnibiotech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The entire 33-page report has been posted on the company’s Web site at http://www.tnibiotech.com/investor-relations/reports
The following is an excerpt of the report: “It is our opinion that TNI presents investors with significant upside from current prices based on a two-fold growth strategy including: the near term commercialization of its existing immunotherapies targeting cancer and HIV/AIDS; coupled with the potential contribution from the phase 3 study of low dose naltrexone (LDN) for use in Crohn’s disease, scheduled to begin in 2014. As the company enters 2013 it should be in a position where ramping revenue run rates not only allow it to be self-funding in regard to clinical development costs, but also for this to translate quickly into an earnings driven growth story for investors with significant potential upside from approvals.”
For more information on the company and its immunotherapies, visit www.tnibiotech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Stellar Biotechnologies, Inc. (SBOTF) KLH Technology Primed to Capture Vast Therapeutic Vaccine and Immune Testing Territory
Stellar has rapidly secured access to a key area of the burgeoning biomedical space through the development and patenting of a renewable method for extraction of KLH, or Keyhole Limpet Hemocyanin (complex oxygen-carrying metalloprotein), a vitally important and highly potent protein. KLH is derived only from the giant keyhole limpet, a kind of sea snail that lives only in the coastal waters off California. Stellar KLH™ Protein is a lucrative product with enormous potential and noteworthy market dynamics.
Stellar has the sole, crucial patent for extraction of this renewable resource and recently (Dec 4) moved to further reinforce their strong IP foundation by filing a patent application on the suKLH technology platform that included composition of matter and usages in a wide range of therapies, as well as manufacturing processes used to farm these limpets in aquaculture. Stellar really has mastered an environmentally sound, non-lethal derivation of pharmaceutical grade (GMP-grade) KLH from the little guys. It is a truly inspiring feat of modern science that blends nature with high-tech. The company is in a leadership position here with the top high molecular weight (hmwKLH) and subunit KLH (suKLH) formulations, with the suKLH formulation’s show-stopping immunogenic potency giving the company a serious edge.
Such high-quality, maximum potency vectors as those in the company’s KLH formulations allow developers to forego incorporation of otherwise dangerous adjuvants (with harmful side-effects) in order to beef up overall immunogenicity in vaccine research. Stellar is positioned to push huge shareholder return numbers due to KLH being critical to over a hundred current clinical trials in bonanza sectors like Alzheimer’s, rheumatoid arthritis, autoimmune disorders, and oncology where, collectively, the net sum quality of life result for millions of people is unquantifiable. The kind of end market territory in therapeutic vaccines and immune testing we are talking about here is incredible, and there is considerable space to develop in KLH-based assays as well, with the company’s Anti-KLH ELISA Test Kits (launched in early April), already showing solid traction in drug screening. It’s a prime example of how this technology can deliver an extremely robust test framework for judging a drug candidate’s capacity for immune system regulation.
This key immunostimulus function of KLH has made it a de facto standard as an antigen among researchers looking to push the envelope of clinical development while retaining high tolerability/safety. Major advances in immune diagnostic testing, like T-cell-dependent antibody response (TDAR, the standard immune competency benchmark for regulators and drug developers), are making KLH look more and more like a sure-fire solution for providing a clinical, trial-ready, standalone injectable for Big Pharma developers.
There are only two other manufacturers in the world for this stuff and it is virtually impossible to synthesize due to the size and complexity of the molecule. The first of those manufacturers, Sigma Aldrich, is dependent on Stellar KLH intermediate as their sole supplier. The second, a German neutricuetical firm named Biosyn (runs a CA-based subsidiary), only produces a specialized suKLH formulation (admittedly failing to produce a potent antibody response and requiring an adjuvant) developed for their own bladder cancer technology, thus any kind of real competition is virtually nil. Stellar has all the ground work laid for capturing the growing range of pharmaceutical KLH applications, and they are ready to go with land-based, scalable aquaculture farming and manufacturing, as well as the IP muscle to back this play.
The value of the company’s KLH formulations from a clinical immune-toxicity testing standpoint are particularly good, and with over a decade of research as well as $16M invested in the technology (half from the company and half from the National Institutes of Health and National Science Foundation), SBOTF today stands behind an extensive trade secret/patents pending IP portfolio that covers the U.S., Canada, France, and Germany. With the only real challenger being the German firm Biosyn and an increasingly stringent stance from FDA and EU regulators on biologicals/viral safety, the long track record for safety of the molecule combines with the company’s established reputation for superior formulation to generate a strong headwind for the Stellar Biotech ship.
The company is basically its own supplier of limpets as well, with the animal population thoroughly cultivated by SBOTF personnel at their land-based facility in Port Hueneme (under license from the US Navy and fully permitted by all relevant regulatory bodies) and any additional requirements satisfied by company divers or business relationships. Stellar can even help pharmaceutical and research clients with custom solutions via their Stellar Business Development unit, providing everything from custom assays and formulations for a specific project, to regulatory dossier support and the development of protocols or reference standards. Full access to the company’s 30-plus years of KLH-related biochemistry and technical expertise is offered as SBOTF actively seeks partnerships that can help exploit the maximum vaccine/immunodiagnostics development potential of the technology pipeline.
Current production capacity roughly exceeds all other commercial capacity and is around upwards of 800g GMP suKLH annually (1.5 Kg of starter material), with a 233% increase in annual output capacity (5Kg) on-track for the next four years, and scalability up to 20 to 100 Kg over the next seven to eight years within striking distance if demand continues to be high. Stellar signed mutual NDAs with seven of the fifteen largest biopharma developers this year and is set to pop as the company continues to draw increased attention from Big Pharma/Biotech concerns.
To learn more about Stellar Biotechnologies, visit www.StellarBiotechnologies.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Stellar has the sole, crucial patent for extraction of this renewable resource and recently (Dec 4) moved to further reinforce their strong IP foundation by filing a patent application on the suKLH technology platform that included composition of matter and usages in a wide range of therapies, as well as manufacturing processes used to farm these limpets in aquaculture. Stellar really has mastered an environmentally sound, non-lethal derivation of pharmaceutical grade (GMP-grade) KLH from the little guys. It is a truly inspiring feat of modern science that blends nature with high-tech. The company is in a leadership position here with the top high molecular weight (hmwKLH) and subunit KLH (suKLH) formulations, with the suKLH formulation’s show-stopping immunogenic potency giving the company a serious edge.
Such high-quality, maximum potency vectors as those in the company’s KLH formulations allow developers to forego incorporation of otherwise dangerous adjuvants (with harmful side-effects) in order to beef up overall immunogenicity in vaccine research. Stellar is positioned to push huge shareholder return numbers due to KLH being critical to over a hundred current clinical trials in bonanza sectors like Alzheimer’s, rheumatoid arthritis, autoimmune disorders, and oncology where, collectively, the net sum quality of life result for millions of people is unquantifiable. The kind of end market territory in therapeutic vaccines and immune testing we are talking about here is incredible, and there is considerable space to develop in KLH-based assays as well, with the company’s Anti-KLH ELISA Test Kits (launched in early April), already showing solid traction in drug screening. It’s a prime example of how this technology can deliver an extremely robust test framework for judging a drug candidate’s capacity for immune system regulation.
This key immunostimulus function of KLH has made it a de facto standard as an antigen among researchers looking to push the envelope of clinical development while retaining high tolerability/safety. Major advances in immune diagnostic testing, like T-cell-dependent antibody response (TDAR, the standard immune competency benchmark for regulators and drug developers), are making KLH look more and more like a sure-fire solution for providing a clinical, trial-ready, standalone injectable for Big Pharma developers.
There are only two other manufacturers in the world for this stuff and it is virtually impossible to synthesize due to the size and complexity of the molecule. The first of those manufacturers, Sigma Aldrich, is dependent on Stellar KLH intermediate as their sole supplier. The second, a German neutricuetical firm named Biosyn (runs a CA-based subsidiary), only produces a specialized suKLH formulation (admittedly failing to produce a potent antibody response and requiring an adjuvant) developed for their own bladder cancer technology, thus any kind of real competition is virtually nil. Stellar has all the ground work laid for capturing the growing range of pharmaceutical KLH applications, and they are ready to go with land-based, scalable aquaculture farming and manufacturing, as well as the IP muscle to back this play.
The value of the company’s KLH formulations from a clinical immune-toxicity testing standpoint are particularly good, and with over a decade of research as well as $16M invested in the technology (half from the company and half from the National Institutes of Health and National Science Foundation), SBOTF today stands behind an extensive trade secret/patents pending IP portfolio that covers the U.S., Canada, France, and Germany. With the only real challenger being the German firm Biosyn and an increasingly stringent stance from FDA and EU regulators on biologicals/viral safety, the long track record for safety of the molecule combines with the company’s established reputation for superior formulation to generate a strong headwind for the Stellar Biotech ship.
The company is basically its own supplier of limpets as well, with the animal population thoroughly cultivated by SBOTF personnel at their land-based facility in Port Hueneme (under license from the US Navy and fully permitted by all relevant regulatory bodies) and any additional requirements satisfied by company divers or business relationships. Stellar can even help pharmaceutical and research clients with custom solutions via their Stellar Business Development unit, providing everything from custom assays and formulations for a specific project, to regulatory dossier support and the development of protocols or reference standards. Full access to the company’s 30-plus years of KLH-related biochemistry and technical expertise is offered as SBOTF actively seeks partnerships that can help exploit the maximum vaccine/immunodiagnostics development potential of the technology pipeline.
Current production capacity roughly exceeds all other commercial capacity and is around upwards of 800g GMP suKLH annually (1.5 Kg of starter material), with a 233% increase in annual output capacity (5Kg) on-track for the next four years, and scalability up to 20 to 100 Kg over the next seven to eight years within striking distance if demand continues to be high. Stellar signed mutual NDAs with seven of the fifteen largest biopharma developers this year and is set to pop as the company continues to draw increased attention from Big Pharma/Biotech concerns.
To learn more about Stellar Biotechnologies, visit www.StellarBiotechnologies.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Wednesday, December 26, 2012
Spam Campaign Continues on USA Graphite, Inc. (USGT)
Numerous unsolicited emails continue to spam USA Graphite and its ticker symbol. Investors should be wary of these emails, as they are completely anonymous and violate the CAN-SPAM Act established by the FTC. As of this time, the company has not provided a public comment on the issue.
Stocks to avoid, due diligence, monitoring investments, key terms in investing and other related topics are covered by us in our Market Basics section. Here we give answers to basic questions regarding stock investments for both new and experienced investors. To view our Market Basics page, visit www.basics.qualitystocks.net.
QualityStocks also helps protect investors by rating thousands of OTC companies and research firms based on their investor relations and transparency practices. To see the list of rated companies, visit: www.qualitystocks.net/companies.php.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Stocks to avoid, due diligence, monitoring investments, key terms in investing and other related topics are covered by us in our Market Basics section. Here we give answers to basic questions regarding stock investments for both new and experienced investors. To view our Market Basics page, visit www.basics.qualitystocks.net.
QualityStocks also helps protect investors by rating thousands of OTC companies and research firms based on their investor relations and transparency practices. To see the list of rated companies, visit: www.qualitystocks.net/companies.php.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
New to Investing? Get Started at QualityStocks!
Investing in publicly traded companies is much easier than what it used to be. Now you can sign up for your own online trading account and be approved in just a few days. From there all you have to do is enter the symbol of the stock you wish to purchase as well as how many shares you want. With so much competition in the online brokerage market today, many are offering low commission rates as well as free independent research tools to make better trading decisions.
Our name emphasizes the commitment we have to connect subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
The QualityStocks Daily Newsletter has been a real hit with both traders and investors because it keeps their finger on the market’s pulse without having to spend countless hours keeping up-to-date. The publication consolidates information from hundreds of Small-Cap and Micro-Cap Online Investment Newsletters in a summary format, plus provides the latest information on the companies we feature.
To sign up for the QualityStocks Daily Newsletter, visit www.signup.qualitystocks.net
The QualityStocks Blog keeps investors up to date on everything related to the small cap and micro cap markets. Alternative fuels and power sources, entertainment media, telecommunications, delivery services, healthcare, and retail are all covered on a regular basis. Investors are also able to learn more about emerging companies that they otherwise would not hear about.
To view the QualityStocks Blog, visit www.blog.qualitystocks.net
Every day we choose a stock that is either poised to either bounce from a recent retrace or displays continuation patterns backed up by technical indicators. While watching these videos, viewers not only find out about a new trading opportunity, but also learn how to effectively apply technical analysis in a real-world setting.
To view the QualityStocks Chart Videos, visit www.videocharts.qualitystocks.net
Stocks to Avoid, Due Diligence, Monitoring Investments, Key Terms in Investing – these are among the topics covered by us in our section called the Market Basics. This is where we give answers to basic questions regarding stock investments for both new and experienced investors.
To visit our Market Basics page, visit www.qualitystocks.net/basics.php
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Our name emphasizes the commitment we have to connect subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
The QualityStocks Daily Newsletter has been a real hit with both traders and investors because it keeps their finger on the market’s pulse without having to spend countless hours keeping up-to-date. The publication consolidates information from hundreds of Small-Cap and Micro-Cap Online Investment Newsletters in a summary format, plus provides the latest information on the companies we feature.
To sign up for the QualityStocks Daily Newsletter, visit www.signup.qualitystocks.net
The QualityStocks Blog keeps investors up to date on everything related to the small cap and micro cap markets. Alternative fuels and power sources, entertainment media, telecommunications, delivery services, healthcare, and retail are all covered on a regular basis. Investors are also able to learn more about emerging companies that they otherwise would not hear about.
To view the QualityStocks Blog, visit www.blog.qualitystocks.net
Every day we choose a stock that is either poised to either bounce from a recent retrace or displays continuation patterns backed up by technical indicators. While watching these videos, viewers not only find out about a new trading opportunity, but also learn how to effectively apply technical analysis in a real-world setting.
To view the QualityStocks Chart Videos, visit www.videocharts.qualitystocks.net
Stocks to Avoid, Due Diligence, Monitoring Investments, Key Terms in Investing – these are among the topics covered by us in our section called the Market Basics. This is where we give answers to basic questions regarding stock investments for both new and experienced investors.
To visit our Market Basics page, visit www.qualitystocks.net/basics.php
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Friday, December 21, 2012
Advaxis, Inc. (ADXS) Utilizes Unique Immunotherapy Platform Technology
One of the hottest areas in medical technology today is the rapidly growing field of immunotherapy, the manipulation of the body’s own immune system to target and combat cellular based diseases such as cancer. The key to immunotherapy, and the biggest challenge, is to develop a mechanism for interacting with and controlling the body’s immune system that is both safe and effective.
Advaxis, a New Jersey based biotechnology company focused on immunotherapies for cancer and infectious diseases, is utilizing a unique platform technology under exclusive license from the University of Pennsylvania, based upon the work of Yvonne Paterson, Ph.D., Professor of Microbiology. The technology utilizes a live attenuated bacterium, Listeria monocytogenes (Lm), bio-engineered to secrete an antigen/adjuvant fusion (Lm-LLO) protein. Her work has shown that Lm-LLO based immunotherapies stimulate the immune system to induce antigen-specific anti-tumor immune responses involving both innate and adaptive arms of the immune system. In addition, this technology could facilitate the immune response by altering the microenvironment of tumors to make them more susceptible to immune attack.
The company’s initial focus has been on immunotherapies targeting HPV-associated diseases, specifically cervical intraepithelial neoplasia (CIN 2/3), recurrent or refractory cervical cancer, as well as head and neck cancer. In addition, they have developed immunotherapies for prostate cancer and HER2 expressing cancers, such as breast, gastric, bladder, brain, pancreatic, and ovarian cancer.
Advaxis has more than fifteen constructs in various stages of development, with their lead construct, ADXS-HPV, currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. In April, 2012, ADXS-HPV was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
For additional information, visit www.Advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Advaxis, a New Jersey based biotechnology company focused on immunotherapies for cancer and infectious diseases, is utilizing a unique platform technology under exclusive license from the University of Pennsylvania, based upon the work of Yvonne Paterson, Ph.D., Professor of Microbiology. The technology utilizes a live attenuated bacterium, Listeria monocytogenes (Lm), bio-engineered to secrete an antigen/adjuvant fusion (Lm-LLO) protein. Her work has shown that Lm-LLO based immunotherapies stimulate the immune system to induce antigen-specific anti-tumor immune responses involving both innate and adaptive arms of the immune system. In addition, this technology could facilitate the immune response by altering the microenvironment of tumors to make them more susceptible to immune attack.
The company’s initial focus has been on immunotherapies targeting HPV-associated diseases, specifically cervical intraepithelial neoplasia (CIN 2/3), recurrent or refractory cervical cancer, as well as head and neck cancer. In addition, they have developed immunotherapies for prostate cancer and HER2 expressing cancers, such as breast, gastric, bladder, brain, pancreatic, and ovarian cancer.
Advaxis has more than fifteen constructs in various stages of development, with their lead construct, ADXS-HPV, currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. In April, 2012, ADXS-HPV was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
For additional information, visit www.Advaxis.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
ZBB Energy Corp. (ZBB) Announces Plans to Join the National Alliance for Advanced Technology Batteries (NAATBatt)
ZBB Energy, a leading developer of intelligent power and energy management technologies, announced that it will be joining the National Alliance for Advanced Technology Batteries (NAATBatt). The alliance will be holding an Annual Conference and Symposium on January 16-18, 2013, in Austin, Texas, where ZBB Energy will present “Ensuring Reliable Power in Unreliable Environments,” which highlights the enabling capabilities of ZBB’s comprehensive power control and energy storage technologies.
NAATBatt is a not-for-profit trade association of foreign and domestic corporations, associations, and research institutions focused on the manufacture of large format advanced batteries for use in transportation and large scale energy storage applications in the United States. Members range from advanced battery and electrode manufactures to material suppliers, vehicle makers, electric utilities, equipment vendors, service providers, universities, and national laboratories.
NAATBatt’s core missions are to grow the North American market for products incorporating advanced energy storage technology and to reduce the cost of those products to U.S. consumers. The core missions of NAATBatt are closely related. NAATBatt operates under the principal that the high cost of electrochemical energy storage, when compared to other technologies, serves as the primary barrier to widespread adoption of large format advanced battery technology. NAATBatt advocates for the adoption of public policies and the development of new technologies and industrial standards that will help reduce the cost to consumers of large format advanced batteries and the products that use them.
NAATBatt provides a platform for its members to work together across industry boundaries in order to address the challenges posed by the adoption of large scale electrochemical energy storage. NAATBatt programs aid in the advancement of energy storage technology and help promote best practices among industry members. NAATBatt helps make the advanced battery industry more efficient and successful by sharing networking opportunities and better information about the North American market for those companies that wish to serve it.
For more information on ZBB Energy, visit www.zbbenergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
NAATBatt is a not-for-profit trade association of foreign and domestic corporations, associations, and research institutions focused on the manufacture of large format advanced batteries for use in transportation and large scale energy storage applications in the United States. Members range from advanced battery and electrode manufactures to material suppliers, vehicle makers, electric utilities, equipment vendors, service providers, universities, and national laboratories.
NAATBatt’s core missions are to grow the North American market for products incorporating advanced energy storage technology and to reduce the cost of those products to U.S. consumers. The core missions of NAATBatt are closely related. NAATBatt operates under the principal that the high cost of electrochemical energy storage, when compared to other technologies, serves as the primary barrier to widespread adoption of large format advanced battery technology. NAATBatt advocates for the adoption of public policies and the development of new technologies and industrial standards that will help reduce the cost to consumers of large format advanced batteries and the products that use them.
NAATBatt provides a platform for its members to work together across industry boundaries in order to address the challenges posed by the adoption of large scale electrochemical energy storage. NAATBatt programs aid in the advancement of energy storage technology and help promote best practices among industry members. NAATBatt helps make the advanced battery industry more efficient and successful by sharing networking opportunities and better information about the North American market for those companies that wish to serve it.
For more information on ZBB Energy, visit www.zbbenergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Noble Roman’s, Inc. (NROM) Masters Growth without Sacrificing Quality
Few would argue that a foundational key to building a business is developing the ability to take a great product or service and to expand it into new forms and markets, but without losing sight of the intrinsic qualities that made the product great in the first place. In the case of Noble Roman’s, which started as a popular pizzeria on the campus of Indiana University back in 1972, it’s always been about maintaining the quality of their food. The company now operates over 1,700 franchsed/licensed outlets throughout the U.S., as well as in Puerto Rico, the Bahamas, Canada, and even Italy. Their food now includes everything that it takes to make great pizza, in addition to breadsticks and cheesesticks, chicken wings, salads, pasta, sandwiches, and even breakfast items.
It wasn’t until the late 1990s that the company decided to go from just operating a string of quick-service pizza restaurants to developing the technology required to operate in numerous types of non-traditional venues, while maintaining the product quality that their extensive fan-base demanded. Today the company provides the best pizza and sub sandwich foodservice products and systems to individual franchisees, but also to entertainment facilities, convenience stores, bowling centers, universities, and military bases.
This includes supplying take-n-bake pizzas to convenience stores as well as a stand-alone offering for grocery stores. One of their fastest growing venues is in groceries, where they provide a deli-based take-n-bake pizza program complemented with other made-for-home retail products. The company, now a multi-million dollar business, continues to see growth in revenue, operating margins, and net income, but remains committed to product quality and taste as the foundation that supports everything else.
For additional information, visit www.NobleRomans.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
It wasn’t until the late 1990s that the company decided to go from just operating a string of quick-service pizza restaurants to developing the technology required to operate in numerous types of non-traditional venues, while maintaining the product quality that their extensive fan-base demanded. Today the company provides the best pizza and sub sandwich foodservice products and systems to individual franchisees, but also to entertainment facilities, convenience stores, bowling centers, universities, and military bases.
This includes supplying take-n-bake pizzas to convenience stores as well as a stand-alone offering for grocery stores. One of their fastest growing venues is in groceries, where they provide a deli-based take-n-bake pizza program complemented with other made-for-home retail products. The company, now a multi-million dollar business, continues to see growth in revenue, operating margins, and net income, but remains committed to product quality and taste as the foundation that supports everything else.
For additional information, visit www.NobleRomans.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Shanda Games Ltd. (GAME) Video Chart for Friday, December 21, 2012
Moving off a bottom at $2.71, GAME just made a chart pattern known as the “Rising Three Method.” This continuation pattern is characterized by a climb followed by a consolidation within the body of the previous candle, followed by a rise to a new high. Although the chart is signaling that the reversal is strengthening off the bottom, the stock faces a tough resistance point at current levels of $3.17.
To view the video chart, visit the following link: http://dtg.fm/AL9k
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
To view the video chart, visit the following link: http://dtg.fm/AL9k
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Christopher S. Destro Joins Atossa Genetics, Inc. (ATOS) as VP – Sales and Marketing
Today, Atossa Genetics announced that Christopher S. Destro has joined the company as its new Vice President of Sales and Marketing. An industry veteran with over 16 years of successful sales and client management expertise, Mr. Destro will oversee product marketing, distribution, and sales. He will report to Dr. Steven C. Quay, MD, PhD, FCAP, Chairman, CEO and President.
“[Atossa] is very fortunate to have Christopher Destro join us as Vice President of Sales and Marketing at this pivotal time,” remarked Dr. Quay. “As we accelerate the national roll-out of our ForeCYTE and ArgusCYTE Breast Health Tests in early 2013, Chris’ extensive industry experience and in-depth market and technical expertise will be invaluable in helping us achieve our ambitious growth objectives.”
From 2007 to 2011, Mr. Destro held multiple prominent positions, including Vice President of Sales, North America, for three divisions of Magellan Biosciences where he managed sales of automated blood culture and automated susceptibility instrumentation for Trek Diagnostics, automated immunochemistry for Dynex, and a lead care platform for Point of Care testing. In July 2011, Thermo Fisher Scientific acquired Magellan, and Mr. Destro became a commercial leader of the Microbiology Division, working with national contracts, distribution channels, and direct sales in the clinical, pharmaceutical, and industrial markets. From 2000 to 2007, Mr. Destro served as Americas Sales Director for International Bioproducts, managing sales of core food pathogen diagnostic (ELISA) products while leading 17 distributors for the United States, Canada, Mexico and Latin America. Mr. Destro holds a Bachelor of Science degree in Microbiology from Ohio State University.
Mr. Destro said, “Atossa Genetics is an exciting and dynamic opportunity and I look forward to working with the team to commercialize the Company’s products and services for the benefit of millions of women. Atossa has already demonstrated the ability to make a difference in women’s lives. Over the past two decades, I have assembled and led teams that have achieved high growth in the diagnostic biotechnology solutions markets. I look forward to contributing to the next phase of Atossa’s growth as we expand the commercialization of our innovative products and services in the U.S.”
He continued, “One of the things that attracted me to Atossa is its novel and revolutionary approach to diagnosing, treating and preventing Breast Cancer. I believe this uniquely positions us to expand the commercialization of our potentially life-saving and market-changing solutions at a time when the need is greater than ever.”
On December 20, 2012, as incentive to join the company, Mr. Destro was awarded an option to purchase a total of 200,000 shares of Atossa’s common stock, par value $0.001 per share, outside the company’s 2010 Stock Option and Incentive Plan. The stock option has an exercise price equal to $4.11 per share, the fair market value on the grant date, and vests over a four-year period from his commencement of service.
For more information on Atossa Genetics, visit www.atossagenetics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“[Atossa] is very fortunate to have Christopher Destro join us as Vice President of Sales and Marketing at this pivotal time,” remarked Dr. Quay. “As we accelerate the national roll-out of our ForeCYTE and ArgusCYTE Breast Health Tests in early 2013, Chris’ extensive industry experience and in-depth market and technical expertise will be invaluable in helping us achieve our ambitious growth objectives.”
From 2007 to 2011, Mr. Destro held multiple prominent positions, including Vice President of Sales, North America, for three divisions of Magellan Biosciences where he managed sales of automated blood culture and automated susceptibility instrumentation for Trek Diagnostics, automated immunochemistry for Dynex, and a lead care platform for Point of Care testing. In July 2011, Thermo Fisher Scientific acquired Magellan, and Mr. Destro became a commercial leader of the Microbiology Division, working with national contracts, distribution channels, and direct sales in the clinical, pharmaceutical, and industrial markets. From 2000 to 2007, Mr. Destro served as Americas Sales Director for International Bioproducts, managing sales of core food pathogen diagnostic (ELISA) products while leading 17 distributors for the United States, Canada, Mexico and Latin America. Mr. Destro holds a Bachelor of Science degree in Microbiology from Ohio State University.
Mr. Destro said, “Atossa Genetics is an exciting and dynamic opportunity and I look forward to working with the team to commercialize the Company’s products and services for the benefit of millions of women. Atossa has already demonstrated the ability to make a difference in women’s lives. Over the past two decades, I have assembled and led teams that have achieved high growth in the diagnostic biotechnology solutions markets. I look forward to contributing to the next phase of Atossa’s growth as we expand the commercialization of our innovative products and services in the U.S.”
He continued, “One of the things that attracted me to Atossa is its novel and revolutionary approach to diagnosing, treating and preventing Breast Cancer. I believe this uniquely positions us to expand the commercialization of our potentially life-saving and market-changing solutions at a time when the need is greater than ever.”
On December 20, 2012, as incentive to join the company, Mr. Destro was awarded an option to purchase a total of 200,000 shares of Atossa’s common stock, par value $0.001 per share, outside the company’s 2010 Stock Option and Incentive Plan. The stock option has an exercise price equal to $4.11 per share, the fair market value on the grant date, and vests over a four-year period from his commencement of service.
For more information on Atossa Genetics, visit www.atossagenetics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Novatel Wireless, Inc. (NVTL) Reaches Three Million Unit Shipment Milestone of 4G LTE Devices and Receives Top Industry Awards for MiFi 2
Novatel Wireless, a prominent supplier of mobile broadband solutions, announced yesterday that since its first shipment in January 2011, Novatel has shipped over three million 4G LTE enabled mobile computing products. On top of reaching this impressive milestone, Novatel Wireless recently won two new LTE innovation awards and multiple Editors’ Choice accolades from tier-one publications for its new 4G LTE MiFi 2.
“We are pleased to celebrate our three millionth shipment of LTE enabled data-only mobile computing products and excited to be honored as the vendor providing continued innovation and the most advanced mobile broadband solutions in the market,” said Peter Leparulo, CEO of Novatel Wireless.
Novatel Wireless’ MiFi 4620L was recently named the winner in the Best LTE Device/Handset category of the 2012 Telecoms LTE North America Awards. The company’s innovative new product was also a CES Innovations Honoree in the Computer Accessories category of the Consumer Electronics Association (CEA)® 2013 Design and Engineering Award. AT&T recently released the MiFi 2 as the MiFi Liberate, and it has already been the recipient of an impressive number of industry awards and Editors’ Choice selections as the best performing and most advanced mobile hotspot on the market.
A recent review by GIZMODO, headlined “AT&T MiFi Liberate: The Best Mobile Hotspot I’ve Ever Used,” stated, “An AT&T LTE MiFi will change your life a little bit.” Highlighting the MiFi Liberate’s bright 2.8-inch color touch-screen display, it continued, “You normally use a computer to change a mobile hotspot’s settings. But this does it on the tiny screen, and it sets the Liberate apart from so much of the competition.” GIZMODO’s review added, “The best part [is] the battery life! This thing will go for days…”
A recent review in PC Magazine noted the advanced feature functionality, ease of use, and reliability of the MiFi Liberate. The review went on to say that the MiFi Liberate “gets you fast 4G LTE data speeds for more than 10 hours on a single charge, plus loads of additional features.” It continued, “The MiFi Liberate for AT&T takes mobile hotspots to the next level. It’s the best hotspot on AT&T, and our Editors’ Choice.”
“We believe our innovative approach, leading design and superior performance are vital factors when serving the mobile broadband market and we’re thrilled to see the acknowledgement and amazing feedback from editors and the industry,” Mr. Leparulo continued.
For further information, please visit www.nvtl.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
“We are pleased to celebrate our three millionth shipment of LTE enabled data-only mobile computing products and excited to be honored as the vendor providing continued innovation and the most advanced mobile broadband solutions in the market,” said Peter Leparulo, CEO of Novatel Wireless.
Novatel Wireless’ MiFi 4620L was recently named the winner in the Best LTE Device/Handset category of the 2012 Telecoms LTE North America Awards. The company’s innovative new product was also a CES Innovations Honoree in the Computer Accessories category of the Consumer Electronics Association (CEA)® 2013 Design and Engineering Award. AT&T recently released the MiFi 2 as the MiFi Liberate, and it has already been the recipient of an impressive number of industry awards and Editors’ Choice selections as the best performing and most advanced mobile hotspot on the market.
A recent review by GIZMODO, headlined “AT&T MiFi Liberate: The Best Mobile Hotspot I’ve Ever Used,” stated, “An AT&T LTE MiFi will change your life a little bit.” Highlighting the MiFi Liberate’s bright 2.8-inch color touch-screen display, it continued, “You normally use a computer to change a mobile hotspot’s settings. But this does it on the tiny screen, and it sets the Liberate apart from so much of the competition.” GIZMODO’s review added, “The best part [is] the battery life! This thing will go for days…”
A recent review in PC Magazine noted the advanced feature functionality, ease of use, and reliability of the MiFi Liberate. The review went on to say that the MiFi Liberate “gets you fast 4G LTE data speeds for more than 10 hours on a single charge, plus loads of additional features.” It continued, “The MiFi Liberate for AT&T takes mobile hotspots to the next level. It’s the best hotspot on AT&T, and our Editors’ Choice.”
“We believe our innovative approach, leading design and superior performance are vital factors when serving the mobile broadband market and we’re thrilled to see the acknowledgement and amazing feedback from editors and the industry,” Mr. Leparulo continued.
For further information, please visit www.nvtl.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Thursday, December 20, 2012
PositiveID Corp. (PSID) Inks Licensing Deal with Boeing
PositiveID, a developer of airborne bio-threat detection systems for the U.S. homeland defense industry and creator of advanced technologies for rapid medical testing and diabetes management, has signed a license and teaming agreement with The Boeing Company.
Per the agreement, which includes a license fee to PositiveID of $2.5 million, Boeing has the exclusive license to manufacture and sell PositiveID’s M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector for the U.S. Department of Homeland Security’s (DHS) BioWatch Generation 3 opportunity, as well as other opportunities that may arise in the North American market.
PositiveID will retain exclusive rights to serve as the reagent and assay supplier of the M-BAND systems to Boeing in the U.S. market, as well as keep the right to sell M-BAND units, reagents, and assays in international markets.
PositiveID’s M-BAND is a bioaerosol monitor with full capability to collect, process, detect, and analyze air samples for the detection of bacteria, viruses, and toxins. Results from individual M-BAND instruments are reported through a secure wireless network in real time to give an accurate and up to date status. The M-BAND touts significant hardiness, operating from -25 to 125 degrees Fahrenheit, for both indoor and outdoor settings. Toxin analysis takes approximately 40 minutes.
For more information, visit www.PositiveIDCorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Per the agreement, which includes a license fee to PositiveID of $2.5 million, Boeing has the exclusive license to manufacture and sell PositiveID’s M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector for the U.S. Department of Homeland Security’s (DHS) BioWatch Generation 3 opportunity, as well as other opportunities that may arise in the North American market.
PositiveID will retain exclusive rights to serve as the reagent and assay supplier of the M-BAND systems to Boeing in the U.S. market, as well as keep the right to sell M-BAND units, reagents, and assays in international markets.
PositiveID’s M-BAND is a bioaerosol monitor with full capability to collect, process, detect, and analyze air samples for the detection of bacteria, viruses, and toxins. Results from individual M-BAND instruments are reported through a secure wireless network in real time to give an accurate and up to date status. The M-BAND touts significant hardiness, operating from -25 to 125 degrees Fahrenheit, for both indoor and outdoor settings. Toxin analysis takes approximately 40 minutes.
For more information, visit www.PositiveIDCorp.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
New Western Energy Corp. (NWTR) Grows Kansas Footprint, Acquires 300 More Contiguous Acres in Hydrocarbon-Rich Chautauqua Arch
New Western Energy has put together a nice portfolio of producing oil wells throughout the Gulf States (Kansas, Oklahoma, Pennsylvania, and Texas), pursuing an acquisitive strategy focused on properties that have shown favorable discovery characteristics. The company today announced yet another important acquisition today, growing their leasehold footprint in Kansas to over 2.55k acres with a choice piece of land, the 300-acre Fields Lease in Chautauqua County.
Alongside the company’s two other key projects in OK, the Phillips Lease (75% WI) and
Glass Lease (75% NRI), as well as projects like the B & W and Smith Leases, with which this new acquisition is contiguous, NWTR looks to be building a serious district foundation. This foundation takes advantage of some ideal geology, an area known as the Chautauqua Arch.
In the south the Central Oklahoma platform merges into the prolific Cherokee basin and to the north there are also multiple vectors for prime Pennsylvanian hydrocarbon sand reservoirs. The shallowness of eastern targets (westerly dipping strata) and abundant pre-Pennsylvanian capacity further south, underscores the inherent value of the region from a production standpoint.
This is prime cut of Pennsylvanian Cherokee shale territory with healthy targets in the Weiser, as well as some Wayside Sands. The host of production targets in the area is huge and well-known, including the eminent Arbuckle reservoir, the Layton, Lola, and Redd Sands, as well as the Oswego Lime and Mississippi Chat. This is a hydrocarbon-rich district and NWTR has wasted no time sizing up the situation, identifying where the smart money is and engaging their acquisition/partnering strategy. Several billion barrels have been pulled out of the Central Kansas Uplift carbonate reservoirs since 1910 and Arbuckle reservoirs alone have pumped out some 2.19B bbls.
President and CEO of NWTR, Javan Khazali, emphasized the significance of the company’s growing land position in the Chautauqua Arch to shareholders and reassured markets that NWTR would continue to aggressively stitch together key production targets in the district. Leaseholds with proven oil and gas reserves like the one acquired today will continue to be the company’s bread and butter, even as the cost saving synergies from the contiguous land position emerge, with upcoming work on the Smith Lease bleeding exploration and development uptick into end game production momentum across the Fields/B&W. New Western plans to kick the E&D at Smith up a notch and relatively soon too, with the improved acreage footprint bolstering company confidence, as well as eagerness to get at the rich energy reservoirs.
NWTR has a solid envelope of oil, gas, and mineral interests which they are continuing to stuff with more goodies for the shareholders.
For more information on New Western Energy, visit www.NewWesternEnergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Alongside the company’s two other key projects in OK, the Phillips Lease (75% WI) and
Glass Lease (75% NRI), as well as projects like the B & W and Smith Leases, with which this new acquisition is contiguous, NWTR looks to be building a serious district foundation. This foundation takes advantage of some ideal geology, an area known as the Chautauqua Arch.
In the south the Central Oklahoma platform merges into the prolific Cherokee basin and to the north there are also multiple vectors for prime Pennsylvanian hydrocarbon sand reservoirs. The shallowness of eastern targets (westerly dipping strata) and abundant pre-Pennsylvanian capacity further south, underscores the inherent value of the region from a production standpoint.
This is prime cut of Pennsylvanian Cherokee shale territory with healthy targets in the Weiser, as well as some Wayside Sands. The host of production targets in the area is huge and well-known, including the eminent Arbuckle reservoir, the Layton, Lola, and Redd Sands, as well as the Oswego Lime and Mississippi Chat. This is a hydrocarbon-rich district and NWTR has wasted no time sizing up the situation, identifying where the smart money is and engaging their acquisition/partnering strategy. Several billion barrels have been pulled out of the Central Kansas Uplift carbonate reservoirs since 1910 and Arbuckle reservoirs alone have pumped out some 2.19B bbls.
President and CEO of NWTR, Javan Khazali, emphasized the significance of the company’s growing land position in the Chautauqua Arch to shareholders and reassured markets that NWTR would continue to aggressively stitch together key production targets in the district. Leaseholds with proven oil and gas reserves like the one acquired today will continue to be the company’s bread and butter, even as the cost saving synergies from the contiguous land position emerge, with upcoming work on the Smith Lease bleeding exploration and development uptick into end game production momentum across the Fields/B&W. New Western plans to kick the E&D at Smith up a notch and relatively soon too, with the improved acreage footprint bolstering company confidence, as well as eagerness to get at the rich energy reservoirs.
NWTR has a solid envelope of oil, gas, and mineral interests which they are continuing to stuff with more goodies for the shareholders.
For more information on New Western Energy, visit www.NewWesternEnergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Case for Viscount Systems, Inc. (VSYS)
In October 2012, SoundView Research issued an investment analysis report on Viscount Systems and The IT Bridge To Physical Security. The report, summarized below, discusses major anticipated technology driven changes underway in the access control industry, and how Viscount Systems offers a unique public investment vehicles in this area, with the potential to generate multiple years of rapidly expanding revenue growth and high margins.
Viscount has launched a suite of new IP-based products that are changing the game in the physical security business, particularly building access control and management. The existing expensive and proprietary “stove-piped” industry is flipping over to modern technology. These systems are being merged with IT-based security tools and methods that leverage existing databases. An IP approach, based on standard IT infrastructure, can be expected to dominate the future of the industry, and Viscount is the only public investment vehicle of its size in this particular space, offering significant returns from current levels.
Considerations driving growth in the industry and Viscount Systems:
• A combination of acute need to comply with regulations plus intense pressure on costs is forcing enterprises to upgrade their existing access control approach and embrace open, modern technologies to lower costs and improve effectiveness.
• Organizations have invested billions in IT-based identity management and logical access security. It’s dawning on everyone that physical access control needs to be managed in the same way as an extension of these systems to eliminate the duplication of cost and effort.
• Viscount Systems has developed their “Freedom” product line into a unique and effective software solution that allows enterprises to manage identity and access management in one place and eliminate the need for expensive proprietary infrastructure.
• Viscount has substantially upgraded their company capability over the last 18 months – expanding their board of directors and advisors, opening their first field office in Washington D.C., and putting the required sales and marketing team in place.
• In the next few quarters Viscount will continue to add new revenues from the Freedom line to their existing core of business in advanced intercom systems. This will enable the company to demonstrate accelerating revenue growth and expanding operating margins.
For additional information, visit www.Viscount.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Viscount has launched a suite of new IP-based products that are changing the game in the physical security business, particularly building access control and management. The existing expensive and proprietary “stove-piped” industry is flipping over to modern technology. These systems are being merged with IT-based security tools and methods that leverage existing databases. An IP approach, based on standard IT infrastructure, can be expected to dominate the future of the industry, and Viscount is the only public investment vehicle of its size in this particular space, offering significant returns from current levels.
Considerations driving growth in the industry and Viscount Systems:
• A combination of acute need to comply with regulations plus intense pressure on costs is forcing enterprises to upgrade their existing access control approach and embrace open, modern technologies to lower costs and improve effectiveness.
• Organizations have invested billions in IT-based identity management and logical access security. It’s dawning on everyone that physical access control needs to be managed in the same way as an extension of these systems to eliminate the duplication of cost and effort.
• Viscount Systems has developed their “Freedom” product line into a unique and effective software solution that allows enterprises to manage identity and access management in one place and eliminate the need for expensive proprietary infrastructure.
• Viscount has substantially upgraded their company capability over the last 18 months – expanding their board of directors and advisors, opening their first field office in Washington D.C., and putting the required sales and marketing team in place.
• In the next few quarters Viscount will continue to add new revenues from the Freedom line to their existing core of business in advanced intercom systems. This will enable the company to demonstrate accelerating revenue growth and expanding operating margins.
For additional information, visit www.Viscount.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
VIASPACE, Inc. (VSPC) Reports Unanimous Vote by Public Services Commission to Approve Giant King Grass-Fueled Electric Power Plant
Today before the opening bell, VIASPACE announced that the St. Croix Public Services Commission (PSC) earlier this week voted to approve Tibbar Energy’s facility design for a 6MW anaerobic generator that uses VIASPACE’s proprietary Giant King(TM) Grass as the source of continuously renewable green energy fuel.
The local “St. Croix Source” publication reported the following:
“A plan to grow 1,500 acres of hybrid Giant King Grass on St. Croix and convert it to bio-fuel for generating electricity took a step forward Tuesday night when the Public Services Commission approved Tibbar Energy USVI’s application for facility design.
By a vote of 4-0 with two absent, the PSC approved the application at its monthly meeting on St. Thomas with St. Croix commissioners Sirri Hamad and Joseph San Martin joining newly elected Commission Chairman M. Thomas Jackson and Vice-Chairwoman Elsie V. Thomas-Turton via teleconference to form a quorum.
Tibbar Energy owner Tanya Coleman and legal counsel Kevin A. Rames presented an overview of the company and adding that Giant King Grass is a fast-growing, high yield grass that is neither genetically modified nor invasive.
The Tibbar representatives told the commission the grass does not compete with other crops, is similar to sugar cane and uses a high-nutrient fertilizer water which will not deplete the soil. Farmers will be provided with free fertilizer.
Tibbar plans to create 40 new jobs in the project, they said, and hopes to harvest 500 to 600 tons a day, running the grass through an anaerobic generator which can produce up to seven kilowatts per hour. Tibbar is pursuing a contractual rate with the Water and Power Authority, Coleman said, adding that Tibbar ‘can begin to provide power by Jan. 1, 2014.’ ”
Dr. Kevin Schewe, VIASPACE’s Chairman, said, “We are certainly pleased to report that our partnership with Tibbar Energy to fuel a clean-energy 6MW anaerobic power plant with Giant King Grass on St. Croix is progressing on schedule. Our business model is to collect regular, predictable license fees as Giant King Grass is harvested by our customers over the life of their projects, and in this case, over a 20 year time frame.”
“In this 1,500 acre project using high-yielding Giant King Grass, we hope to harvest 500-600 tons of Giant King Grass per day and the harvesting is scheduled to begin in St. Croix in 2013,” he continued. “We are actively engaged in significantly larger acreage projects and in projects that we expect to serve as co-developer of the power plant where, in addition to our license fees, we could also generate recurring revenue from the sale of local electricity. We are genuinely excited about the pace and extent of our corporate progress as we head into 2013.”
For more information on VIASPACE and its Giant King Grass, visit www.viaspace.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The local “St. Croix Source” publication reported the following:
“A plan to grow 1,500 acres of hybrid Giant King Grass on St. Croix and convert it to bio-fuel for generating electricity took a step forward Tuesday night when the Public Services Commission approved Tibbar Energy USVI’s application for facility design.
By a vote of 4-0 with two absent, the PSC approved the application at its monthly meeting on St. Thomas with St. Croix commissioners Sirri Hamad and Joseph San Martin joining newly elected Commission Chairman M. Thomas Jackson and Vice-Chairwoman Elsie V. Thomas-Turton via teleconference to form a quorum.
Tibbar Energy owner Tanya Coleman and legal counsel Kevin A. Rames presented an overview of the company and adding that Giant King Grass is a fast-growing, high yield grass that is neither genetically modified nor invasive.
The Tibbar representatives told the commission the grass does not compete with other crops, is similar to sugar cane and uses a high-nutrient fertilizer water which will not deplete the soil. Farmers will be provided with free fertilizer.
Tibbar plans to create 40 new jobs in the project, they said, and hopes to harvest 500 to 600 tons a day, running the grass through an anaerobic generator which can produce up to seven kilowatts per hour. Tibbar is pursuing a contractual rate with the Water and Power Authority, Coleman said, adding that Tibbar ‘can begin to provide power by Jan. 1, 2014.’ ”
Dr. Kevin Schewe, VIASPACE’s Chairman, said, “We are certainly pleased to report that our partnership with Tibbar Energy to fuel a clean-energy 6MW anaerobic power plant with Giant King Grass on St. Croix is progressing on schedule. Our business model is to collect regular, predictable license fees as Giant King Grass is harvested by our customers over the life of their projects, and in this case, over a 20 year time frame.”
“In this 1,500 acre project using high-yielding Giant King Grass, we hope to harvest 500-600 tons of Giant King Grass per day and the harvesting is scheduled to begin in St. Croix in 2013,” he continued. “We are actively engaged in significantly larger acreage projects and in projects that we expect to serve as co-developer of the power plant where, in addition to our license fees, we could also generate recurring revenue from the sale of local electricity. We are genuinely excited about the pace and extent of our corporate progress as we head into 2013.”
For more information on VIASPACE and its Giant King Grass, visit www.viaspace.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
IGI Laboratories, Inc. (IG) Appoints Dr. Kenneth Miller as Senior Vice President – R&D
Yesterday, New Jersey-based generic topical pharmaceutical company IGI Laboratories announced that it has appointed Dr. Kenneth Miller as its Senior Vice President of R&D, effective December 17, 2012.
Jason Grenfell-Gardner, IGI’s President and CEO, remarked, “Dr. Miller’s appointment brings significant practical experience in generic topical pharmaceuticals and leadership that will allow us to accelerate the growth of our ANDA pipeline. This pipeline is the key to growing IGI’s generic business, and we’re excited to have Dr. Miller leading our R&D team.”
Dr. Miller has an extensive career with over 20 years of topical and transdermal experience in branded and generic pharmaceutical product development. Prior to IGI, he held various leadership positions at Mylan Technologies, eventually rising to Senior Director in 2008. As head of product development, Dr. Miller oversaw the development of topical and transdermal patches, including Mylan’s Fentanyl Transdermal System which received the DIANA Award for Best New Product Introduction in 2005.
In addition to his contributions to product development, Dr. Miller was responsible for technical evaluation of Mylan’s intellectual property, with four US Patents and six World Patents on product design and manufacture. Additional patents are currently pending.
Prior to Mylan, Ken held positions in both industry and academia serving on the faculties of UAMS (Pharmaceutics), Penn State (Chemical Engineering), and Utah (Dermatology). He has a BSChE degree from Carnegie Mellon University, an MSChE degree from West Virginia University, and a PhD from the University of Florida.
For more information, visit www.igilabs.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Jason Grenfell-Gardner, IGI’s President and CEO, remarked, “Dr. Miller’s appointment brings significant practical experience in generic topical pharmaceuticals and leadership that will allow us to accelerate the growth of our ANDA pipeline. This pipeline is the key to growing IGI’s generic business, and we’re excited to have Dr. Miller leading our R&D team.”
Dr. Miller has an extensive career with over 20 years of topical and transdermal experience in branded and generic pharmaceutical product development. Prior to IGI, he held various leadership positions at Mylan Technologies, eventually rising to Senior Director in 2008. As head of product development, Dr. Miller oversaw the development of topical and transdermal patches, including Mylan’s Fentanyl Transdermal System which received the DIANA Award for Best New Product Introduction in 2005.
In addition to his contributions to product development, Dr. Miller was responsible for technical evaluation of Mylan’s intellectual property, with four US Patents and six World Patents on product design and manufacture. Additional patents are currently pending.
Prior to Mylan, Ken held positions in both industry and academia serving on the faculties of UAMS (Pharmaceutics), Penn State (Chemical Engineering), and Utah (Dermatology). He has a BSChE degree from Carnegie Mellon University, an MSChE degree from West Virginia University, and a PhD from the University of Florida.
For more information, visit www.igilabs.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Boston Therapeutics, Inc. (BTHE) Approved to Commence Clinical Study of SUGARDOWN®
Boston Therapeutics has been given the green light to initiate a clinical study of the efficacy and safety of SUGARDOWN® in combination with a standard meal on post-meal sugar and insulin blood levels in patients with Type ll diabetes that have been treated with metformin, the world’s leading anti-diabetes prescription.
Boston Therapeutics has received approval by the French East IV Committee of Protection of Persons (Strasbourg) and the Ministry of Health; the company anticipates filing similar applications in the U.S., Hong Kong, and South Korea in 2013.
SUGARDOWN® previously was clinically proven to reduce the after meal elevation of blood sugar. For the next round of clinical trials, the company plans to enroll 24 patients with Type ll diabetes in the French study and expects to start recruiting patients in January 2013.
“In a clinical study, we saw significant reductions of post-meal elevation of blood sugar in healthy, non-diabetic patients who were overweight,” Dr. Hana Chen Walden, consulting medical director of Boston Therapeutics stated in the press release. “It is important for people, especially those with diabetes, to control their blood sugar levels throughout the day. We believe SUGARDOWN® may help millions of people to better manage their blood sugar.”
In October 2012, Boston Therapeutics announced that the FDA had approved its petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of metformin.
For more information visit www.bostonti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Boston Therapeutics has received approval by the French East IV Committee of Protection of Persons (Strasbourg) and the Ministry of Health; the company anticipates filing similar applications in the U.S., Hong Kong, and South Korea in 2013.
SUGARDOWN® previously was clinically proven to reduce the after meal elevation of blood sugar. For the next round of clinical trials, the company plans to enroll 24 patients with Type ll diabetes in the French study and expects to start recruiting patients in January 2013.
“In a clinical study, we saw significant reductions of post-meal elevation of blood sugar in healthy, non-diabetic patients who were overweight,” Dr. Hana Chen Walden, consulting medical director of Boston Therapeutics stated in the press release. “It is important for people, especially those with diabetes, to control their blood sugar levels throughout the day. We believe SUGARDOWN® may help millions of people to better manage their blood sugar.”
In October 2012, Boston Therapeutics announced that the FDA had approved its petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of metformin.
For more information visit www.bostonti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Wednesday, December 19, 2012
GreenHunter Energy, Inc. (GRH) Expands Appalachia Transport Fleet Capacity Ahead of Disposal Upgrades, Adds HAZMAT Certification
GreenHunter Energy today updated markets on the status of their wholly owned GreenHunter Water, LLC subsidiary, reporting that the company has put in orders to expand the size of its trucking fleet serving the unconventional shale operators in the Appalachians (Marcellus and Utica plays in Ohio, Pennsylvania, and West Virginia).
President and COO of GRH, Jonathan Hoopes, commented on the addition of the six new Peterbilt 388 Bobtails (three with 100 bbl vacuum tanks and three with identical tanks certified for HAZMAT), noting that the company is running at full capacity in the region and could really use the new operational muscle. The expansion of the Appalachia truck fleet from a mere five at the outset of 2012, to now 31 transport trucks, is a clear indication of the direction GRH is headed and as more and more regional operators come to know/rely on the exemplary services the company can provide, the fleet will likely expand further.
When you throw in the new GRH disposal facilities slated to come on-line relatively soon, you can see that the company is prepping for increased business volume, balancing out the trucking capacity and disposal capacity ahead of growth perfectly. Today’s announcement is also something of a milestone for regional operations as the company has hitherto lacked certified equipment for handling liquids mixed with hydrocarbons, something which is generally no problem since the vast majority of such hydrocarbon-laced water is usually gravity separated on-site anyways. However, there are some pads in this difficult terrain that don’t have the equipment for this kind of on-site separation and thus GRH can now capture even more market space through the fleet expansion, offering a potentially clutch service to this growing customer-base.
This move basically puts GRH in the oil transport business while riveting on some much-needed capacity in the thriving, hydrocarbon-rich Appalachia region. This region has a solid future for such production, so it makes good sense for the company to be growing their overall infrastructural footprint at this phase. A winning combination of absolutely vital water transport and disposal well services has quickly built up a warm brand identity for the company among sector operators doing difficult work in this difficult region.
In the Appalachians the work is dirty, difficult, and brutal. Companies like GRH, who put the operator’s needs first and have capacity on-site, on time, and ready to go when it’s needed can make a killing here. GreenHunter really has put together an attractive portfolio of Total Water Management Solutions™ for these guys, with several key innovations developed from an operator-centric point of view, like the flexible Frac-Cycle™ system that allows flowback and produced water to be recycled into clean brine or fresh water, their bleeding-edge well head management and compliance solution RAMCAT™ (Remote Access Management Compliance Asset Tracking), or the company’s latest edition, a completely customizable, 10k plus bbl temporary water storage tank system (complete with robust interlocking steel panels for safe/rapid deployment), the MAG Tank™.
As part of the purchase, GRH has bolstered an existing commercial loan facility with a local bank in the heart of the Appalachians, bumping the window up to $3.3M. GreenHunter expects to take delivery of the new hardware early in 2013 (late January) and will be offering this new capacity to hungry hydrocarbon developers in the region as soon as late Q1.
For more information on GreenHunter Energy, visit www.GreenHunterEnergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
President and COO of GRH, Jonathan Hoopes, commented on the addition of the six new Peterbilt 388 Bobtails (three with 100 bbl vacuum tanks and three with identical tanks certified for HAZMAT), noting that the company is running at full capacity in the region and could really use the new operational muscle. The expansion of the Appalachia truck fleet from a mere five at the outset of 2012, to now 31 transport trucks, is a clear indication of the direction GRH is headed and as more and more regional operators come to know/rely on the exemplary services the company can provide, the fleet will likely expand further.
When you throw in the new GRH disposal facilities slated to come on-line relatively soon, you can see that the company is prepping for increased business volume, balancing out the trucking capacity and disposal capacity ahead of growth perfectly. Today’s announcement is also something of a milestone for regional operations as the company has hitherto lacked certified equipment for handling liquids mixed with hydrocarbons, something which is generally no problem since the vast majority of such hydrocarbon-laced water is usually gravity separated on-site anyways. However, there are some pads in this difficult terrain that don’t have the equipment for this kind of on-site separation and thus GRH can now capture even more market space through the fleet expansion, offering a potentially clutch service to this growing customer-base.
This move basically puts GRH in the oil transport business while riveting on some much-needed capacity in the thriving, hydrocarbon-rich Appalachia region. This region has a solid future for such production, so it makes good sense for the company to be growing their overall infrastructural footprint at this phase. A winning combination of absolutely vital water transport and disposal well services has quickly built up a warm brand identity for the company among sector operators doing difficult work in this difficult region.
In the Appalachians the work is dirty, difficult, and brutal. Companies like GRH, who put the operator’s needs first and have capacity on-site, on time, and ready to go when it’s needed can make a killing here. GreenHunter really has put together an attractive portfolio of Total Water Management Solutions™ for these guys, with several key innovations developed from an operator-centric point of view, like the flexible Frac-Cycle™ system that allows flowback and produced water to be recycled into clean brine or fresh water, their bleeding-edge well head management and compliance solution RAMCAT™ (Remote Access Management Compliance Asset Tracking), or the company’s latest edition, a completely customizable, 10k plus bbl temporary water storage tank system (complete with robust interlocking steel panels for safe/rapid deployment), the MAG Tank™.
As part of the purchase, GRH has bolstered an existing commercial loan facility with a local bank in the heart of the Appalachians, bumping the window up to $3.3M. GreenHunter expects to take delivery of the new hardware early in 2013 (late January) and will be offering this new capacity to hungry hydrocarbon developers in the region as soon as late Q1.
For more information on GreenHunter Energy, visit www.GreenHunterEnergy.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The Guitammer Company, Inc. (GTMM) Picks Up Good Vibrations
The power of communication is one of the most dramatic accomplishments of the modern age, transforming, among other things, the way people are entertained. From the earliest sound recordings and motion pictures, with silent movies giving way to sound, black and white giving way to color, followed eventually by wide screen, stereo, and 3D. It’s all about making people feel like they are part of the event, part of the action. One game-changing technology has inevitably made way for another.
The latest revolution comes from an Ohio based company that is changing the way theaters and theater goers around the world experience movies and broadcast events. The Guitammer Company has invented a way to communicate the subtle, and often not-so-subtle, vibrations inherent in a sporting or musical or movie event that make the person feel like they are there, experiencing it live. It’s the sensation that some people attempt to capture by simply turning up the volume to annoyingly high levels, volumes that can even damage hearing.
But the Guitammer technology has nothing to do with volume, using instead ultra-low frequency sound waves that are felt rather than heard. Sound waves are picked up from the recorded event, such as the enhanced sound from a movie, and are converted to low frequency vibrations that shake the theater seat or even home couches, creating an undeniable feeling of being there, part of the action. It’s a technology they’ve already installed in theaters all over the world, with in-home versions also available.
To see Guitammer’s latest home theater specials, visit http://dtg.fm/gtmm-holiday-deals
For more information on the company, visit www.guitammer.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The latest revolution comes from an Ohio based company that is changing the way theaters and theater goers around the world experience movies and broadcast events. The Guitammer Company has invented a way to communicate the subtle, and often not-so-subtle, vibrations inherent in a sporting or musical or movie event that make the person feel like they are there, experiencing it live. It’s the sensation that some people attempt to capture by simply turning up the volume to annoyingly high levels, volumes that can even damage hearing.
But the Guitammer technology has nothing to do with volume, using instead ultra-low frequency sound waves that are felt rather than heard. Sound waves are picked up from the recorded event, such as the enhanced sound from a movie, and are converted to low frequency vibrations that shake the theater seat or even home couches, creating an undeniable feeling of being there, part of the action. It’s a technology they’ve already installed in theaters all over the world, with in-home versions also available.
To see Guitammer’s latest home theater specials, visit http://dtg.fm/gtmm-holiday-deals
For more information on the company, visit www.guitammer.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Posts (Atom)
